Wedbush lowered its price target for BioCryst Pharmaceuticals to $17 from $18 after the company’s third-quarter results.

Nov 4, 2026, 2:09 PM ETOpinionRead the original at marketscreener.com

Neutral

Wedbush lowered its target from $18 to $17 but kept its Outperform rating. The lower target points one way and the unchanged rating points the other, leaving BioCryst's share outlook unchanged.

BCRX · BioCryst Pharmaceuticals

AI read · Neutral

The AI's read

The lower target suggests Wedbush sees less potential for the shares than before. Keeping its Outperform rating still signals a favorable view. Neither change outweighs the other, so the report does not shift BioCryst's share outlook.

Get alerts for BCRX

Follow BioCryst Pharmaceuticals (BCRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BCRX

Free on the App Store and Google Play, or on the web.